Related Experiment Video

Updated: Nov 1, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K

HFBD: a biomarker knowledge database for heart failure heterogeneity and personalized applications

Hongxin He1,2, Manhong Shi2,3, Yuxin Lin2

  • 1Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610212, China.

Bioinformatics (Oxford, England)
|June 24, 2021
PubMed

Insights

A new Heart Failure Biomarker Knowledge Database (HFBD) catalogs 868 biomarkers from scientific literature. This resource aids understanding of heart failure (HF) heterogeneity and supports personalized precision medicine approaches.

Area of Science:

  • Biomedical Informatics
  • Cardiovascular Research
  • Genomics and Proteomics

Background:

  • Heart failure (HF) is a global cardiovascular disease with significant incidence.
  • Precision medicine requires comprehensive biomarker identification for personalized HF diagnosis and treatment.
  • Understanding HF heterogeneity necessitates a centralized data resource for multi-level biomarker information.

Purpose of the Study:

  • To establish a centralized knowledge database for heart failure biomarkers (HFBD).
  • To systematically collect and organize HF biomarker data from scientific literature.
  • To facilitate the understanding of HF heterogeneity and support personalized medicine strategies.

Main Methods:

  • Manual data collection and knowledge extraction from PubMed literature.
  • Inclusion of 2618 records and 868 distinct HF biomarkers (single and combined).
  • Classification of biomarkers by type (proteins, RNAs, DNAs) and level (molecular, image, cellular, physiological).

Main Results:

  • The HFBD contains 868 HF biomarkers derived from 1237 articles.
  • Biomarkers are annotated with biological, clinical, and experimental details.
  • The database offers a user-friendly interface for accessing HF biomarker information.

Conclusions:

  • The HFBD provides a unique resource for systematic understanding of HF heterogeneity.
  • This database supports personalized diagnosis and treatment in the era of precision medicine.
  • The HFBD is openly available to the research community.
Abstract

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

332
In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.9K

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
93
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
128
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
60
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
538
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
283